Advaxis, Inc. (NASDAQ:ADXS) announced that it had made a few changes to the board of directors. As per the reports, company’s CEO and Executive Vice President, Gregory Mayes has been included in the Board of Directors.

Insights of Matter

Advaxis is known for world-class products and services related to cancer immunotherapies. The entire senior management team of Advaxis is pleased to welcome Mayes to company’s Board of Directors. According to Daniel J. O’Connor, CEO & President, Advaxis, it’s great to have a business leader like Mayes on company’s board. Throughout his career, Mayes has tried to add value to the organizations he has worked with in the best possible way.

He further added that Advaxis is growing at a swift pace and looking forward to coming up with treatments that can help cancer patients. At such a crucial time, Mayes can play a crucial role by helping Advaxis touch all new heights.

Mayes joined Advaxis in 2013 after spending over two decades in the pharmaceutical industry. It’s the result of his active involvement in major key-decisions that Advaxis has managed to improve its development pipeline as well as financial position. He worked tirelessly to establish clinical collaborations with many organizations, including one with MedImmune and Merck. During his tenure, Advaxis has witnessed an exponential growth in the numbers of institutional shareholders.

Prior joining Advaxis, Mayes worked at senior management level with ImClone Systems, AstraZeneca Pharmaceuticals, and Eli Lilly. While working with ImClone, he was chosen as the lead resource for the integration of ImClone with none other than Eli Lilly; moreover, he also played a crucial role in the commercialization and clinical development of ERBITUX. During his tenure with Astra Zeneca, Mayes provided legal support for the commercialization and development of five oncology products.

Mayes did graduation from Syracuse University and juris doctorate from Temple University School of Law. He looks forward to justifying the faith and confidence that Advaxis board has showed in him.